Drug Monograph
Apixaban 2.5mg, 5mg; tabs.
Select the therapeutic use below to view the corresponding drug monograph
Visit the related Resource Center for drug monographs, news, CME and other clinical tools for this drugs’ particular therapeutic area.
News
The researchers found the risk of GI bleeding was lower for apixaban versus dabigatran or rivaroxaban.
AHA 2018
While the use of NSAIDs was low in the ARISTOTLE trial, NSAID users had a higher risk for bleeding than non-users.
News
Lower rates seen for ischemic stroke or systemic embolism, GI bleeding or intracranial hemorrhage.
News
Different factor concentrates can reverse some of the alterations in hemostasis attributed to apixaban.
News
Primary venous thromboembolism prophylaxis with apixaban, an oral direct Factor Xa inhibitor, in ambulatory cancer patients undergoing first- or second-line chemotherapy for advanced or metastatic cancer, is safe and well tolerated.
AHA 2015
Older patients, females, and those with comorbidities were more likely to be on multiple medications.